SABCS 2025: Latest developments in multigene testing in early breast cancer
Published on 5 January 2026
Prof Nadia Harbeck (LMU University Hospital, Munich, Germany) and Prof Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) discuss the latest developments in multigene testing in early breast cancer from SABCS 2025.
They touch on the Oncodetect and Oncotype DX tests and their impact on practice, while Prof Curigliano discusses multimodal AI models that integrate gene panels, pathology and clinical data.
He highlights that the multimodal ICM+ AI (imaging, clinical, and expanded molecular) model shows improved accuracy for overall and late recurrence prediction compared to traditional tools, helping better identify which patients may need extended endocrine therapy and enabling more personalised long-term risk assessment
The panel further discusses the TAILORx and NSABP B-59/GBG-96-GeparDouze trial data, prognostic versus predictive gene testing and conclude by talking about liquid biopsy testing.